Sensible Biotechnologies
YC S21Oxford, GB · Founded 2021 · Delaware corporation · 24 employees · 6 known investors
Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.
Also known as Genbiotics
AI & Machine LearningBiotechDeep TechHealthtechSynthetic BiologyManufacturingTherapeuticsBiotechnologyUnited KingdomEuropePartly Remote
Founders & leadership· Y Combinator alumni (S21)
Sensible Biotechnologies was founded in 2021 by Miroslav Gasparek and Marian Kupculak.
MG
Miroslav Gasparekin𝕏CEO and Co-FounderHe studied bioengineering at Imperial College London and engineering at Oxford, and has worked on Slovak biosecurity policy development.
MK
Marian KupculakinCo-founder · Chief Science OfficerMarian Kupculak holds a PhD in Biochemistry from the University of Oxford and has over 9 years of experience in biochemistry and molecular biology, with expertise in cellular engineering and downstream processing. He is co-founder and Chief Scientific Officer of Sensible Biotechnologies, which develops manufacturing platforms for mRNA production.
Investors · 6
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 1 round · 2023
▶$1.8MraisedFeb 2023 · 18 investors · BiotechnologyRule 506(b)
▶$1.8MraisedFeb 2023 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marian KupculakExecutive Officer, Director
- Miroslav GasparekExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.8M
- Proceeds to insiders
- $100K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Sana Biotechnology6 shared keywordsSana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
Senti Biosciences6 shared keywordsSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
bio5 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Shennon Biotechnologies5 shared keywordsShennonBio develops immunotherapy technologies using microfluidic engineering, computational biology, and immunology to advance T cell engineering for cancer treatment. The company serves therapeutic development organizations working on cell and gene therapies.
Companies competing with Sensible Biotechnologies for the same Google search keywords, organic and paid, via search-intersection analysis.
Companies House · registry record
View on Companies House ↗- Registered name
- SENSIBLE BIOTECHNOLOGIES LIMITED
- Company number
- 14628427
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 31 Jan 2023
- Registered office
- 3rd Floor 1 Ashley Road, Altrincham, Cheshire, WA14 2DT
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology72190 — Other research and experimental development on natural sciences and engineering
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 30 Jan 2026 · next due 13 Feb 2027
Current officers · 2
- Miroslav Gasparek — director, appointed 31 Jan 2023
- Marian Kupculak — director, appointed 31 Jan 2023
Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Sensible Biotechnologies do?
- Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.
- Who founded Sensible Biotechnologies?
- Sensible Biotechnologies was founded by Miroslav Gasparek, Marian Kupculak in 2021.
- Who are Sensible Biotechnologies's investors?
- Sensible Biotechnologies's investors include Civilization Ventures Management, Llc, KAYA, Recode Ventures, Y Combinator, ZAKA VC, BlueYard Capital.
- How much funding has Sensible Biotechnologies raised?
- Sensible Biotechnologies has disclosed $1.8M raised across 1 round.
- Where is Sensible Biotechnologies headquartered?
- Sensible Biotechnologies is headquartered in Oxford, GB.